MX2012003982A - Pirrolidinas n-substituidas. - Google Patents

Pirrolidinas n-substituidas.

Info

Publication number
MX2012003982A
MX2012003982A MX2012003982A MX2012003982A MX2012003982A MX 2012003982 A MX2012003982 A MX 2012003982A MX 2012003982 A MX2012003982 A MX 2012003982A MX 2012003982 A MX2012003982 A MX 2012003982A MX 2012003982 A MX2012003982 A MX 2012003982A
Authority
MX
Mexico
Prior art keywords
sub
mdm2
pyrrolidines
interactions
inhibitors
Prior art date
Application number
MX2012003982A
Other languages
English (en)
Inventor
David Joseph Bartkovits
Xin-Jie Chu
Jin Jun Liu
Tina Morgan Ross
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012003982A publication Critical patent/MX2012003982A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se proporcionan compuestos de la fórmula (ver fórmula (I)) en donde X, Y, R1, R2, R3, R3, R4, y R5 son como se describe aqui, y sus enantiómeros y sales y ésteres farmacéuticos aceptables que son útiles como agentes anticáncer.
MX2012003982A 2009-10-14 2010-10-11 Pirrolidinas n-substituidas. MX2012003982A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25141309P 2009-10-14 2009-10-14
US34562610P 2010-05-18 2010-05-18
PCT/EP2010/065159 WO2011045257A1 (en) 2009-10-14 2010-10-11 Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions

Publications (1)

Publication Number Publication Date
MX2012003982A true MX2012003982A (es) 2012-05-08

Family

ID=43567698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003982A MX2012003982A (es) 2009-10-14 2010-10-11 Pirrolidinas n-substituidas.

Country Status (12)

Country Link
US (1) US8017607B2 (es)
EP (1) EP2488491A1 (es)
JP (1) JP2013507416A (es)
KR (1) KR20120081210A (es)
CN (1) CN102548963A (es)
AU (1) AU2010305914A1 (es)
BR (1) BR112012008485A2 (es)
CA (1) CA2774512A1 (es)
IL (1) IL218018A0 (es)
IN (1) IN2012DN02487A (es)
MX (1) MX2012003982A (es)
WO (1) WO2011045257A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939778C (en) * 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2142562B1 (en) 2007-03-28 2013-07-03 President and Fellows of Harvard College Stitched polypeptides
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
EP2603600B1 (en) 2010-08-13 2018-11-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012076513A1 (en) * 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス,インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP6387013B2 (ja) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Hdm2阻害薬としての置換されたイミダゾピリジン類
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
CZ2002203A3 (cs) 1999-07-21 2002-08-14 Astrazeneca Ab Spirooxindolové deriváty
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
CA2752738C (en) 2005-02-22 2014-05-27 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
AU2007207052B2 (en) 2006-01-18 2012-07-12 F. Hoffmann-La Roche Ag CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors
MX2009000285A (es) 2006-06-30 2009-06-08 Schering Corp Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
NZ591024A (en) * 2008-09-18 2013-01-25 Hoffmann La Roche Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
JP2013507416A (ja) 2013-03-04
CN102548963A (zh) 2012-07-04
US8017607B2 (en) 2011-09-13
EP2488491A1 (en) 2012-08-22
IL218018A0 (en) 2012-04-30
WO2011045257A1 (en) 2011-04-21
CA2774512A1 (en) 2011-04-21
US20110086854A1 (en) 2011-04-14
BR112012008485A2 (pt) 2019-09-24
AU2010305914A1 (en) 2012-03-08
KR20120081210A (ko) 2012-07-18
IN2012DN02487A (es) 2015-08-28

Similar Documents

Publication Publication Date Title
MX2012003982A (es) Pirrolidinas n-substituidas.
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
TW200801000A (en) Spiroindolinone derivatives
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
MY160596A (en) Spiroindolinone pyrrolidines
IL193620A0 (en) Spiroindolinone derivatives
IL205354A0 (en) Spiroindolinone derivatives
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
TW200612958A (en) Substituted imidazole derivatives
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2010006332A (es) Derivados de espiroindolinona como agentes anticancer.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
WO2011143772A9 (en) Inhibitors of hiv replication
TN2009000178A1 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
WO2009140101A3 (en) Imidazopyridine compounds useful as mmp-13 inhibitors
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
MX2012005596A (es) Derivados de difenil azepano como inhibidores de reabsorcion de monoaminas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal